Patient characteristics of 103 individuals infected with HCV
. | Group A . | Group B . | Group C . | Group D . |
|---|---|---|---|---|
| No. | 23 | 6 | 55 | 19 |
| % IVDU | 68 | 67 | 87 | 67 |
| Prior interferon | None | None | None | None |
| Mean age, y (range) | 44 (19-59) | 45 (39-50) | 45 (28-56) | 44 (33-56) |
| % men | 75 | 67 | 61 | 76 |
| % white | 83 | 100 | 61 | 71 |
| Median HCV VL, IU/mL*,† | 454 000 | < 600 | 1 620 000 | < 600 |
| % genotype 1 | 60 | NA | 72 | NA |
| Mean ALT, U/L (range)† | 75 (17-201) | 19 (4-27) | 75 (6-342) | 37 (10-95) |
| Biopsy, inflammatory score | 4.5¶ | NA | 5.4# | NA |
| Biopsy, fibrosis score | 2.5¶ | NA | 2.6# | NA |
| CD4+/mm3 (range)‡,§ | 940 (227-1677) | 1267 (772-1887) | 526 (64-1340) | 521 (4-1430) |
| CD8+/mm3 (range)‡,§ | 434 (41-784) | 692 (303-1361) | 980 (267-2514) | 1033 (510-2325) |
| CD4+/CD8+ ratio‡,§ | 2.4 | 2.1 | 0.61 | 0.66 |
| ART status (%)∥ | NA | NA | 26/55 (47) | 14/19 (74) |
| Median HIV-1 VL, copies/mL∥ | NA | NA | 3170 | < 50 |
| % HIV-1 VL < 50 copies/mL (%) | NA | NA | 17/55 (31) | 11/21 (52) |
. | Group A . | Group B . | Group C . | Group D . |
|---|---|---|---|---|
| No. | 23 | 6 | 55 | 19 |
| % IVDU | 68 | 67 | 87 | 67 |
| Prior interferon | None | None | None | None |
| Mean age, y (range) | 44 (19-59) | 45 (39-50) | 45 (28-56) | 44 (33-56) |
| % men | 75 | 67 | 61 | 76 |
| % white | 83 | 100 | 61 | 71 |
| Median HCV VL, IU/mL*,† | 454 000 | < 600 | 1 620 000 | < 600 |
| % genotype 1 | 60 | NA | 72 | NA |
| Mean ALT, U/L (range)† | 75 (17-201) | 19 (4-27) | 75 (6-342) | 37 (10-95) |
| Biopsy, inflammatory score | 4.5¶ | NA | 5.4# | NA |
| Biopsy, fibrosis score | 2.5¶ | NA | 2.6# | NA |
| CD4+/mm3 (range)‡,§ | 940 (227-1677) | 1267 (772-1887) | 526 (64-1340) | 521 (4-1430) |
| CD8+/mm3 (range)‡,§ | 434 (41-784) | 692 (303-1361) | 980 (267-2514) | 1033 (510-2325) |
| CD4+/CD8+ ratio‡,§ | 2.4 | 2.1 | 0.61 | 0.66 |
| ART status (%)∥ | NA | NA | 26/55 (47) | 14/19 (74) |
| Median HIV-1 VL, copies/mL∥ | NA | NA | 3170 | < 50 |
| % HIV-1 VL < 50 copies/mL (%) | NA | NA | 17/55 (31) | 11/21 (52) |
Group A was monoinfected, HCV chronic, HIV-1 Ab negative, and HCV Ab positive with HCV RNA greater than 600. Group B was monoinfected, HCV controller, HIV-1 Ab negative, and HCV Ab positive with HCV RNA fewer than 600. Group C was HIV-1+, HCV chronic, HIV-1 Ab positive, and HCV Ab positive with HCV RNA greater than 600. Group D was HIV-1+, HCV controller, HIV-1 Ab positive, and HCV Ab positive with HCV RNA fewer than 600. Cutoff for significance was P < .05, two-tailed. No patient had a prior history of interferon treatment for chronic hepatitis C. Biopsy scores are tabulated on the Ishak staging system.18 The maximum inflammatory score is 18, and the maximum fibrosis score is 6. Genotype data were unavailable for 12 subjects in group C. Ab indicates antibody; VL, viral load; IVDU, intravenous drug use; IU, international units; ALT, alanine aminotransferase; ART, antiretroviral therapy; NA, not applicable
Significant difference between groups A and C.
Significant difference between groups A and C (RNA > 600) and groups B and D (RNA < 600).
Significant difference between groups A and B (all HIV-1 negative) versus groups C and D (all HIV-1 positive).
Data regarding T-cell subset frequencies were collected for 26 of 29 HCV monoinfected individuals.
Significant difference between groups C and D.
n = 18.
n = 21.